American Medical Technologies Inc/De - Notification that Annual Report will be submitted late (NT 10-K)
01 Abril 2008 - 3:07PM
Edgar (US Regulatory)
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
(Check
one):
|
|
x
Form 10-K
|
o
Form 20-F
|
o
Form 11-K
|
o
Form 10-Q
|
o
Form 10-D
|
|
|
o
Form N-SAR
|
o
Form N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period
Ended:
|
December 31, 2007
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
For the
Transition Period Ended:
|
|
|
|
|
|
|
|
|
|
Read Instructions (on back
page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
|
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I REGISTRANT INFORMATION
AMERICAN
MEDICAL TECHNOLOGIES, INC.
|
Full Name of
Registrant
|
|
AMERICAN
DENTAL TECHNOLOGIES, INC.
|
Former Name if
Applicable
|
|
5655
BEAR LANE
|
Address of
Principal Executive Office
(Street and
Number)
|
|
CORPUS
CHRISTI, TX 78405
|
City, State and
Zip Code
|
PART II RULES 12b-25(b) AND (c)
If the subject
report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
|
(a)
|
The reason
described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense
|
x
|
(b)
|
The subject
annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q or subject distribution report on
Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountants
statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
|
PART III NARRATIVE
State below in reasonable detail why Forms 10
-
K, 20
-
F, 11
-
K, 10
-
Q, 10
-
D, N
-
SAR, N
-
CSR, or the transition
report or
portion
thereof, could not be filed within the prescribed time period.
The Company has experienced
a delay in completing the information necessary for inclusion in its December
31, 2007 Form 10-KSB Annual Report. The
Company expects to file its Form 10-KSB Annual Report within the allotted
extension period.
(Attach extra
Sheets if Needed)
PART IV OTHER INFORMATION
(1)
|
Name and
telephone number of person to contact in regard to this notification
|
|
BARBARA WOODY
|
|
361
|
|
289-1145
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
(2)
|
Have all other
periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940
during the preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed ? If answer is no, identify
report(s).
|
|
|
|
|
|
|
|
x
Yes
o
No
|
|
|
|
|
|
|
(3)
|
Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|
|
|
|
|
|
|
|
x
Yes
o
No
|
|
|
|
|
|
|
|
If so, attach an
explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the
results cannot be made.
|
The significant changes in results of operations from
2006 were: an increase in revenues from
$2,712,335 in 2006 to $3,165,399 in 2007 primarily as a result of the addition
of the Spectrum product line in April 2006, commissions earned from the Direct
Crown product line added in April 2007 and the sale of inventory from
discontinued product lines; an increase in gross profit as a percentage of
revenues from 50% in 2006 to 53% in 2007 due to a higher gross margin on the
Spectrum product line than existing product lines and commissions earned from
the addition of the Direct Crown product line which were partially offset by an
increase in the Companys inventory valuation allowance; an increase in
selling, general and administrative expenses from $2,841,547 in 2006 to
$2,845,731 in 2007 primarily due to employee stock option expenses, license
fees and other professional fees; a net loss of ($1,421,992) in 2006 compared
to a net loss of ($952,856) in 2007; an increase in other income from $67,231
in 2006 to $242,918 primarily due to compensation for consulting services and
the write off of customer credits from prior years; and the basic and diluted
loss per share of ($0.17) in 2006 compared to ($0.11) in 2007.
AMERICAN MEDICAL TECHNOLOGIES, INC.
(Name of Registrant as
Specified in Charter)
has caused this
notification to be signed on its behalf by the undersigned hereunto duly
authorized.
Date
|
March 31, 2008
|
|
By
|
/s/ Barbara
Woody
|
|
|
|
Barbara Woody,
Controller
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is
signed on behalf of the registrant by an authorized representative (other than
an executive officer), evidence of the representatives authority to sign on
behalf of the registrant shall be filed with the form.
|
ATTENTION
|
|
Intentional misstatements or
omissions of fact constitute Federal Criminal Violations (See 18 U.S.C.
1001).
|
American Medical Technol... (CE) (USOTC:ADLI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
American Medical Technol... (CE) (USOTC:ADLI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024